Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients
Nora Liebers, Claudius Speer, Louise Benning, Peter‐Martin Bruch, Isabelle Kraemer, Julia Meißner, Paul Schnitzler, Hans‐Georg Kräusslich, Peter Dreger, Carsten Müller‐Tidow, Isabel Poschke, Sascha Dietrich
Abstract
Three reports address the protection of the vulnerable population of patients with hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest that some patients who fail to mount a B-cell response to vaccine may nevertheless have protective T cell responses. As a group, these reports suggest that patients should continue to be immunized with additional doses to attempt to improve immune response but that they need to maintain the precautions recommended for the unvaccinated.
Topics & Concepts
MedicineImmunologyVaccinationPandemicLymphomaCoronavirus disease 2019 (COVID-19)Immune systemPopulationRituximabCD20VirologyInternal medicineDiseaseInfectious disease (medical specialty)Environmental healthSARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impactsCAR-T cell therapy research